📊 PRO: This Week in Visuals
MSFT AAPL META LLY MA MCD QCOM BKNG SBUX KLAC MDLZ ABNB TEAM HLT GM RBLX HOOD YUM XYZ KHC LYV RDDT GRAB DUOL TWLO SNAP ALGN ROKU CFLT ETSY
Welcome to the Saturday PRO edition of How They Make Money.
Over 200,000 subscribers turn to us for business and investment insights.
In case you missed it:
Premium subscribers get:
📊 Monthly reports: 200+ companies visualized.
📩 Tuesday articles: Exclusive deep dives and insights.
📚 Access to our archive: Hundreds of business breakdowns.
PRO subscribers get everything PLUS:
📩 Saturday PRO reports: Timely insights on the latest earnings.
Today at a glance:
💻 Microsoft: Cloud Reaccelerates
📱Apple: iPhone Holds, China Fades
♾️ Meta: Scaling the AI Stack
💊 Eli Lilly: GLP-1 Boom, CVS Blow
💳 Mastercard: Cross-Border Resilience
🍟 McDonald's: Consumer Pressure
📲 Qualcomm: Tepid Outlook
🏝️ Booking: Travel Uncertainty
☕️ Starbucks: Turnaround Takes Time
🔬 KLA: AI Drives Momentum
🍪 Mondelez: Cocoa Pressure Builds
🛖 Airbnb: Next Chapter
☁️ Atlassian: Longer Deal Cycle
🏨 Hilton: Resilient Pipeline
🚗 GM: Tariffs Shake the Outlook
👾 Roblox: Bookings Rebound
🪶 Robinhood: Growth on All Fronts
🌮 YUM Brands: Taco Bell Shines
🔲 Block: Macro Pressure Mounts
🌭 Kraft Heinz: Demand Still Weak
🎤 Live Nation: Big Year Ahead
👽 Reddit: Ads and AI Power Growth
🛵 Grab: Profits Accelerate
🦉 Duolingo: Max Momentum
💬 Twilio: AI Drives Confidence
👻 Snap: Cloudy Outlook
🦷 Align: Innovation Lifts Outlook
📺 Roku: Streaming Acquisition
📊 Confluent: Cloud Growth Slows
📦 Etsy: Buyer Weakness Lingers
FROM OUR PARTNERS
AI Agents That Handle Your SOC 2 Compliance While You Sleep
Remember when SOC 2 took months? Delve's AI agents just ended that. They work around the clock, running your compliance end-to-end while you do the whole “company building” thing.
The world's hottest startups are already on board:
→ 11x deployed Delve and unlocked $2.3M in enterprise deals that were stuck in compliance limbo.
→ Bland AI went from "we need SOC 2" to "$500k in revenue" in 1 week.
Ready to get compliant fast?
💰 Book a demo with promo code AEI1K for $1000 off compliance + free AirPods Max when you sign.
⚡ App Economy Insights readers get white-glove onboarding from Delve's founders.
1. 💻 Microsoft: Cloud Reaccelerates
Microsoft delivered a strong Q3 FY25 (March quarter), with revenue up 13% Y/Y to $70.1 billion (a $1.6 billion beat) and EPS rising 18% to $3.46 ($0.24 beat). Growth was broad-based—but Azure led the charge, surging 35% in constant currency, up from 31% in Q2. AI accounted for 16 points of Azure growth, accelerating from 13% in the prior quarter. Microsoft Cloud grew 20% Y/Y to $42.4 billion (a $0.2 billion beat). CapEx came in at $21.4 billion—slightly below last quarter—as expansion moderated after 10 new data centers launched.
What’s next? Microsoft guides for Q4 revenue of $73.2–74.3 billion (above consensus), with Azure expected to grow 34–35%. While CapEx will increase in FY26, the pace should slow. CEO Satya Nadella highlighted Microsoft's infrastructure scalability, record AI workloads, and enterprise traction across SQL, Teams, and Fabric. Despite macro uncertainty, Microsoft looks well-positioned to lead the AI platform race—powered by OpenAI integrations and resilient enterprise demand.
2. 📱Apple: iPhone Holds, China Fades
Apple’s Q2 FY25 (March quarter) revenue rose 5% Y/Y to $95.4 billion (a $840 million beat), with EPS up 8% to $1.65 ($0.03 beat). iPhone sales were up 2% at $46.8 billion, while Services jumped 12% to $26.7 billion—marking another quarter of double-digit growth. Mac ($8.0B) and iPad ($6.4B) both beat expectations, though Wearables fell 5% and missed. Gross margin slightly improved to 47%, boosting net income to $24.8 billion. Apple returned $29 billion to shareholders via buybacks and a 4% dividend hike.
The drag? China. Revenue in the region fell 2% to $16.0 billion, pressured by competition and geopolitical tension. Tariffs are expected to add $900 million in costs for the June quarter, accelerating Apple’s supply chain shift—most US-bound iPhones will soon be made in India, with other devices from Vietnam. Looking ahead, Apple guided for low- to mid-single-digit revenue growth next quarter as it gears up for major AI updates and a fall hardware refresh.
3. ♾️ Meta: Scaling the AI Stack
Meta posted a strong Q1 FY25, with revenue up 16% Y/Y to $42.3 billion ($950 million beat) and EPS surging 37% to $6.43 ($1.21 beat). Ad growth drove the beat, with a 10% rise in prices and 5% more impressions, despite tariffs and macro pressure.
User engagement remained high across the Family of Apps, with daily active users up 6% to 3.43 billion. Meta AI now has nearly 1 billion monthly users, while Threads has surpassed 350 million. Reality Labs losses persisted, but operating margin expanded to 41%, helping generate $10.3 billion in free cash flow.
The big pivot? AI infrastructure. Meta raised its full-year CapEx outlook to $64–72 billion (up from $60–65 billion previously), citing increased hardware costs and data center investments. Mark Zuckerberg unveiled a new standalone Meta AI app to compete more directly with ChatGPT, while outlining plans to embed AI across the company’s tools and platforms. Q2 revenue is expected at ~$44 billion (midpoint), above consensus. Despite trade war tension and regulatory noise, Meta appears to be winning investor confidence in its long-term AI strategy.
4. 💊 Eli Lilly: GLP-1 Boom, CVS Blow
Eli Lilly posted Q1 revenue growth of 45% Y/Y to $12.7 billion (in line), driven by Mounjaro ($3.8B) and Zepbound ($2.3B). EPS of $3.34 missed by $0.12 due to a $1.6 billion acquired R&D charge, leading management to lower full-year non-GAAP EPS guidance to $20.78–22.28 (down from $22.50–24.00). Still, gross margin rose to 83.5%, and US GLP-1 sales remained the clear growth engine, despite flat Verzenio and mixed Zepbound sentiment tied to a label update for heart failure.
But sentiment took a hit. Shares dropped after CVS Caremark excluded Zepbound from its standard formulary in favor of Novo’s Wegovy, fueling access concerns despite Lilly’s reassurances. CEO Dave Ricks emphasized Lilly’s edge in efficacy, manufacturing, and oral delivery, spotlighting Orforglipron’s trial win. The company reaffirmed FY25 revenue guidance of $58–61 billion (+32% at midpoint), brushed off tariff risks, and called for policy incentives favoring pharma innovation. Despite volatility, the GLP-1 thesis remains intact, with data catalysts on the horizon.